CA-BELKIN
Belkin, a leading consumer electronics brand for 40 years, today announces a first-of-its-kind power bank providing fast charge capabilities for newer Apple Watch models1 and iPhone simultaneously, on-the-go. Able to fully charge the Apple Watch Series 8 and Apple Watch Series 7 from 0% to 80% in about 45 minutes, and Apple Watch Ultra 0% to 80% in about an hour,2 the BoostCharge Pro Fast Wireless Charger is the perfect solution for portable power in a pinch.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230516006027/en/
Belkin BoostCharge™ Fast Wireless Charger for Apple Watch + Power Bank 10K (Photo: Business Wire)
The powerful new charger was designed in California by Belkin’s award-winning design team and intricately engineered to fit most Apple Watch band sizes and styles. It leverages the latest in technology to charge the Apple Watch Series 8 fourteen times, or iPhone 14 twice3.
Product features:
- Supports fast charging for Apple Watch Series 8 and Apple Watch Series 7 from 0% to 80% in about 45 minutes, and Apple Watch Ultra 0% to 80% in about an hour2
- Built with a 20W USB-C PD port for fast charging the power bank itself as well as an additional device
- Provides up to 36 hours of video playback for iPhone 144 with 10,000mAh cell capacity
- Built with overcharge protection and fully certified by USB-IF and MFi to deliver safe, fast, efficient power
- Supports wireless charging for AirPods Pro (2nd generation)
- Includes 12-inch USB-C cable for charging power bank
- Ships in plastic-free retail packaging
- Connected Equipment Warranty covers up to $2500 for peace of mind
The BoostCharge Pro Fast Wireless Charger for Apple Watch + Power Bank 10K is now available for $99.99 USD on Belkin.com.
Media kit is available for download HERE.
About Belkin
Belkin is an accessories market leader delivering power, protection, productivity, connectivity, audio, security, and home automation solutions for a broad range of consumer electronics and enterprise environments. Designed in Southern California and sold in more than 100 countries around the world, Belkin has been a market leader and innovator for 40 years. Its dedication to people-inspired design and quality informs everything from user testing and prototyping process to regulatory compliance, manufacturing and warranty programs. In 2018 Belkin International merged with Foxconn Interconnect Technology to broaden its global influence while maintaining its steadfast focus on R&D, community, education and sustainability.
____________________________
1 Fast charging is only compatible with Apple Watch Series 7, Apple Watch Series 8, and Apple Watch Ultra. Other models will have regular charge times.
2 Testing conducted by Belkin in October 2022; devices tested with latest watchOS 9.0.1 software. Actual results will vary depending on varying factors, including device age, model and usage environment, for individual users.
3 Data based on internal lab testing. Actual results will vary depending on varying factors for individual users.
4 Maximum additional video playback hours calculated by comparing the cell capacity of this power bank with the maximum video playback hours achievable by the iPhone 14 under normal conditions. Actual results will vary depending on varying factors for individual users.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230516006027/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom